Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells

Cell Proliferation

Volumn 41, Issue 1, 2008, Pages 59-85

  Vazquez Martin, A ^a   Colomer, R ^b   Brunet, J ^a   Lupu, R ^c,d   Menendez, J A ^a  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b MD ANDERSON CANCER CENTER   (Spain)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Evanston North western Healthcare Research Institute (ENHRI)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; C 75; CISPLATIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; PHOSPHOR TYROSINE; PHOSPHOR TYROSINE ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CATALYSIS; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DEVICE; DIPLOIDY; DNA HISTONE INTERACTION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FATTY ACID SYNTHASE GENE; FATTY ACID SYNTHESIS; GENE; GENE ACTIVATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PLASMID; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; CELL LINE; CELL PROLIFERATION; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FATTY ACID SYNTHETASE COMPLEX; HUMANS; MAMMARY GLANDS, HUMAN; MICE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; TRANSFECTION;

BOVINAE;

EID: 38549147538     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/j.1365-2184.2007.00498.x     Document Type: Article

References (73)

1. Albanell J, Gascon P (2005) Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 6, 259 274.
2. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP (2005) Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene 24, 39 46.
3. Baron A, Migita T, Tang D, Loda M (2004) Fatty acid synthase: a metabolic oncogene in prostate cancer? J. Cell. Biochem. 91, 47 53.
4. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911 917.
5. Bui T, Thompson CB (2006) Cancer's sweet tooth. Cancer Cell 9, 419 420.
6. Caron de Fromentel C, Nardeux PC, Soussi T, Lavialle C, Estrade S, Carloni G, Chandrasekaran K, Cassingena R (1985) Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information. Exp. Cell Res. 160, 83 94.
7. Ciardiello F, Gottardis M, Basolo F, Pepe S, Normanno N, Dickson RB, Bianco AR, Salomon DS (1992) Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol. Carcinog. 6, 43 52.
8. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7, 505 516.
9. Costello LC, Franklin RB (2006) Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution. Mol. Cancer 5, 59.
10. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR (1996) MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am. J. Pathol. 148, 313 319.
11. Dils R, Carey EM (1975) Fatty acid Synthase from rabbit mammary gland. Meth. Enzymol. 35, 74 83.
12. Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86, 839 848.
13. Gaffney EV (1982) A cell line (HBL-100) established from human breast milk. Cell Tissue Res. 227, 563 568.
14. Garber K (2004) Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl. Cancer Inst. 96, 1805 1806.
15. Garber K (2006) Energy deregulation: licensing tumors to grow. Science 312, 1158 1159.
16. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891 899.
17. Giunciuglio D, Culty M, Fassina G, Masiello L, Melchiori A, Paglialunga G, Arand G, Ciardiello F, Basolo F, Thompson EW (1995) Invasive phenotype of MCF10A cells overexpressing c-Ha-ras and c-erbB-2 oncogenes. Int. J. Cancer 63, 815 822.
18. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M (2004) The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell 5, 253 261.
19. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647 1655.
20. Greenstein JP (1954) Biochemistry of Cancer. New York : Academic Press.
21. Gross ME, Shazer RL, Agus DB (2004) Targeting the HER-kinase axis in cancer. Semin Oncol. 31 (1 Suppl. 3 9 20.
22. Hu X, Juneja SC, Maihle NJ, Cleary MP (2002) Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J. Natl. Cancer Inst. 94, 1704 1711.
23. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341 354.
24. Johnston SR, Leary A (2006) Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc) 42, 441 453.
25. Kim JW, Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66, 8927 8930.
26. Knowles LM, Smith JW (2007) Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics 8, 168.
27. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630 1639.
28. Krief P, Saint-Ruf C, Bracke M, Boucheix C, Billard C, Billard M, Cassingena R, Jasmin C, Mareel M, Azzarone B (1989) Acquisition of tumorigenic potential in the human myoepithelial HBL100 cell line is associated with decreased expression of HLA class I, class II and integrin beta 3 and increased expression of c-myc. Int. J. Cancer 43, 658 664.
29. Kuhajda FP (2000) Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16, 202 208.
30. Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66, 5977 5980.
31. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, Pasternack GR (1994) Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. USA 91, 6379 6383.
32. Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA (2000) Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA 97, 3450 3454.
33. Li Q, Ahmed S, Loeb JA (2004) Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells. Cancer Res. 64, 7078 7085.
34. Lupu R, Menendez JA (2006a) Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators? Endocrinology 147, 4056 4066.
35. Lupu R, Menendez JA (2006b) Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr. Pharm. Biotechnol. 7, 495 502.
36. Maier T, Jenni S, Ban N (2006) Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science 311, 1258 1262.
37. Marlhens F, Saint-Ruf C, Nardeux P, Lavialle C, Brouty-Boye D, Dutrillaux B, Cassingena R (1988) Karyotype evolution of the human HBL-100 cell line and mapping of the integration site of SV40 DNA. Ann. Genet 31, 81 86.
38. Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Radiat. Oncol. Biol. Phys. 58, 903 913.
39. Medes G, Thomas A, Weinhouse S (1953) Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13, 27 29.
40. Menendez JA, Lupu R (2004) Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch. Immunol. Ther. Exp. (Warsz) 52, 414 426.
41. Menendez JA, Lupu R (2006) Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr. Opin. Clin. Nutr. Metab. Care 9, 346 357.
42. KIP1, BRCA1, and NF-kappaB. Int. J. Oncol. 24, 591 608.
43. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R (2004b) Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int. J. Oncol. 24, 1369 1383.
44. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R (2004c) Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc. Natl. Acad. Sci. USA 101, 10715 10720.
45. Menendez JA, Mehmi I, Verma VA, Teng PK, Lupu R (2004d) Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol. Carcinog. 41, 164 178.
46. Menendez JA, Colomer R, Lupu R (2005a) Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? Med. Hypotheses 64, 342 349.
47. Menendez JA, Vellon L, Colomer R, Lupu R (2005b) Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity. Int. J. Cancer 115, 19 35.
48. Menendez JA, Lupu R, Colomer R (2005c) Obesity, fatty acid synthase, and cancer: serendipity or forgotten causal linkage? Mol. Genet. Metab. 84, 293 295.
49. Menendez JA, Decker JP, Lupu R (2005d) In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J. Cell. Biochem. 94, 1 4.
50. Menendez JA, Lupu R, Colomer R (2005e) Targeting fatty acid synthase: potential for therapeutic intervention in Her-2/neu-overexpressing breast cancer. Drug News Perspect. 18, 375 385.
51. Menendez JA, Vellon L, Oza BP, Lupu R (2005f) Does endogenous fatty acid metabolism allow cancer cells to sense hypoxia and mediate hypoxic vasodilatation? Characterization of a novel molecular connection between fatty acid synthase (FAS) and hypoxia-inducible factor-1alpha (HIF-1alpha)-related expression of vascular endothelial growth factor (VEGF) in cancer cells overexpressing her-2/neu oncogene. J. Cell. Biochem. 94, 857 863.
52. Merida I, Avila-Flores A (2006) Tumor metabolism: new opportunities for cancer therapy. Clin. Transl. Oncol. 8, 711 716.
53. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH (1993) Xenograft model of progressive human proliferative breast disease. J. Natl. Cancer Inst. 85, 1725 1732.
54. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr. Relat. Cancer 10, 1 21.
55. Olayioye MA (2001) Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 3, 385 389.
56. Ookhtens M, Kanna R, Lyon I, Baker N (1984) Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor. Am. J. Physiol. 247, R146 R153.
57. Pizer ES, Chrest FJ, Digiuseppe JA, Han WF (1998) Pharmacological inhibition of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res. 58, 4611 4615.
58. Pizer ES, Thupari J, Han WF, Pinn ML, Chrest FJ, Frehywot GL, Townsend CA, Kuhajda FP (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res. 60, 213 218.
59. Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S, Zimmermann J, Febbo P, Loda M (2006) The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. Cancer Res. 66, 8625 8632.
60. Santner SJ, Dawson PJ, Tait L, Soule, HD, Eliason, J, Mohamed, AN, Wolman, SR, Heppner, GH, Miller, FR (2001) Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res. Treat. 65, 101 110.
61. Shaw RJ (2006) Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18, 598 608.
62. Smith S (1994) The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J. 8, 1248 1259.
63. Souttou B, Hamelin R, Crepin M (1994) FGF2 as an autocrine growth factor for immortal human breast epithelial cells. Cell Growth Differ. 5, 615 623.
64. Swinnen JV (2001) Increased lipogenesis in steroid-responsive cancer cells: mechanisms of regulation, role in cancer cell biology and perspectives on clinical applications. Verh. K. Acad. Geneeskd. Belg. 63, 321 333.
65. Swinnen JV, Brusselmans K, Verhoeven G (2006) Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9, 358 365.
66. Wada T, Qian XL, Greene MI (1990) Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339 1347.
67. Wakil S (1989) Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 28, 4523 4530.
68. Warburg O (1956) On the origin of cancer cells. Science 123, 309 314.
69. Warburg O, Posener KEN (1924) Uber den stoffwechsel der carcinomzelle. Biochem. Z 152, 309.
70. Weiss L, Hoffmann GE, Schreiber R, Andres H, Fuchs E, Körber E, Kolb HJ (1986) Fatty-acid biosynthesis in man, a pathway of minor importance. Biol. Chem. 367, 905 912.
71. Worthylake R, Opresko LK, Wiley HS (1999) ErbB-2 amplification inhibits down regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J. Biol. Chem. 274, 8865 8874.
72. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127 137.
73. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV, Kuhajda FP (2003) Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 63, 7330 7337.